tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and AquaBounty Technologies (AQB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sangamo Biosciences (SGMOResearch Report) and AquaBounty Technologies (AQBResearch Report).

Sangamo Biosciences (SGMO)

In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences, with a price target of $10.00. The company’s shares closed last Thursday at $4.30, close to its 52-week low of $4.02.

According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -11.8% and a 27.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $14.60.

See today’s best-performing stocks on TipRanks >>

AquaBounty Technologies (AQB)

In a report released today, Ben Klieve from Lake Street reiterated a Buy rating on AquaBounty Technologies, with a price target of $8.00. The company’s shares closed last Thursday at $1.35, close to its 52-week low of $1.30.

Klieve has an average return of 55.8% when recommending AquaBounty Technologies.

According to TipRanks.com, Klieve is ranked #385 out of 7891 analysts.

AquaBounty Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $6.25, implying a 337.1% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SGMO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More